Eloquest and Omni-stat Form Alliance for Advanced Hemostasis
Eloquest Healthcare and Omni-stat Medical Strategic Partnership
In an exciting development, Eloquest Healthcare, Inc. and Omni-stat Medical, Inc. have announced their strategic partnership aimed at revolutionizing hemostatic solutions in acute care settings. This collaboration is set to enhance access to proven technologies that are critical in managing bleeding during medical emergencies.
Expanding Access to Advanced Hemostatic Products
As part of this partnership, Eloquest will actively promote Omni-Stat’s innovative range of hemostatic products within the U.S. acute care market. The focus will particularly be on intensive care units and vascular access procedures, where rapid response to bleeding events is crucial. By integrating these advanced solutions into clinical practice, the companies aim to empower healthcare providers to deliver timely and effective interventions.
Enhancements in Clinical Outcomes
Omni-Stat's proprietary gauze products are specifically engineered to quickly control bleeding, making them invaluable in critical environments where quick action can significantly impact patient outcomes. The introduction of these products aligns seamlessly with Eloquest Healthcare's mission: to significantly elevate patient care standards, particularly in vascular access management.
Statements from Leadership
Tim O'Halla, President and CEO of Eloquest Healthcare, expressed enthusiasm about the partnership, stating, "We are excited to partner with Omni-stat Medical to bring these proven hemostatic solutions into more hospitals and ICUs across the country. This agreement reflects our continued commitment to aligning with best-in-class technologies that complement our portfolio." He emphasized the potential this partnership holds in enabling clinicians to improve care and patient outcomes, especially during critical phases of treatment.
Collaboration Goals and Future Vision
Gina Milner, Director of US Commercial Operations at Omni-stat Medical, echoed these sentiments by highlighting the six-month collaboration between the two entities. “Omni-Stat is proud to collaborate with Eloquest Healthcare. Their expertise in the acute care market makes them the ideal partner, facilitating the adoption of our hemostatic products,” she mentioned. Both companies are motivated to support clinicians with solutions that not only stop blood loss but also reduce the time required to stabilize patients.
About Eloquest Healthcare, Inc.
Eloquest Healthcare operates as a subsidiary of Ferndale Pharma Group, Inc., focusing on developing solutions that enhance clinical outcomes, elevate the quality of care, and reduce costs. Through continuous innovation, Eloquest provides tools that aid healthcare professionals in achieving optimal efficiency and superior patient care. Further details about Eloquest can be found on their official website.
About Omni-stat Medical, Inc.
Omni-stat Medical is recognized as a pioneer in hemostatic technologies, specializing in rapid and effective solutions for controlling bleeding of all severities. The company's dedication to clinical innovation is evident in its products, which seek to improve patient management and healthcare resource use. Their commitment is to lessen risks related to blood loss while enhancing overall patient safety.
Contact Information
For inquiries regarding Eloquest Healthcare, please contact:
Crysta Seneski, Vice President of Marketing
cseneski@eloquesthealthcare.com
248-586-8482
For inquiries regarding Omni-stat Medical, please contact:
Gina Milner, Director, US Commercial Operations
gina.milner@omnistatmedical.com
215-237-0566
Frequently Asked Questions
What is the aim of the Eloquest and Omni-stat partnership?
The partnership aims to advance hemostatic solutions within acute care settings, particularly in intensive care units.
What products will Eloquest promote?
Eloquest will promote Omni-Stat’s proprietary hemostatic gauze products designed for rapid bleeding control.
Who are the key leaders involved in this partnership?
The partnership involves Tim O'Halla from Eloquest and Gina Milner from Omni-stat Medical.
How does this partnership benefit healthcare providers?
This collaboration provides clinicians with proven solutions that enhance patient care and improve outcomes during critical treatment phases.
What is the vision for the future of this collaboration?
The companies aim to increase the adoption and accessibility of hemostatic products across more healthcare facilities.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
